The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$275

For the biopharmaceutical industry, 2017 was marked by noteworthy innovation as well as disappointments across therapy areas, set against a backdrop of remarkable advances in technology in healthcare and the growing presence of biosimilars. Each of the major therapeutic areas — oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology — saw a range of clinical breakthroughs, setbacks in R&D, and advances in digital health. Within oncology, immunology, and ophthalmology, the late-stage development and launches of biosimilars continued to gradually reshape the competitive landscape in 2017.

Scope

GlobalData’s The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area provides an insight-rich overview of the key events and trends that shaped the industry during 2017. Within each of the major therapeutic areas covered, GlobalData’s analysts have identified the most impactful happenings during 2017 — such as product launches and label expansions, losses of patent protection and market exclusivity, and key clinical trial data readouts — and provided expert insight on the implications of each event.

Reasons to Buy

Gain insight into the key trends that shaped the biopharmaceutical industry in 2017 by therapeutic area.

Understand major 2017 events across drug development, disease competitive landscapes, and digital health.

Identify the top 20 companies and the top 10 drugs in each therapeutic area by 2017 revenue.

The top 20 companies in 2017 in each of the following major therapeutic areas are mentioned: oncology
immunology
neurology
cardiovascular diseases
metabolic disorders
infectious diseases
and ophthalmology. In addition
key players in the digital health space who made progress in 2017 are included.

Table of Contents

Introduction

Oncology

Top Players in Oncology in 2017

CAR-T Approvals Fuel Optimism in Difficult-to-Treat Diseases, But Feasibility Questions Remain

Checkpoint Inhibitors Continued to Demonstrate Clinical Benefit Across a Wide Range of Tumors

As CPIs Gather More Market Approvals, Combination Regimens Will Be the Main Strategy to Differentiate their Clinical Benefit

PARP Inhibitors Market Sees Surge in Activity in 2017

PARP Inhibitors Landscape Undergoes Momentous Changes

Approval of Cancer Therapeutics a Tipping Point in the Oncology Biosimilar Space

Digital Health Advances in Oncology in 2017 Made Significant Progress in Various Areas of Clinical Treatment

Immunology

Top Players in Immunology in 2017

Increasing Development of JAK Inhibitors Creates Welcome Competition Among Oral Small Molecules

Interleukin Inhibitors Have the Potential to Become First-Line Therapies Across Autoimmune Diseases

Biosimilars Steal Increasing Market Share in Immunology Indications, but Face Challenges in the US Before Reaching Peak Sales

Digital Advances Provide Promising Solutions for Chronic Disease Management

Neurology

Top Players in Neurology in 2017

Two Failures Within the 5-HT6 Receptor Antagonist Class Means the Options for Alzheimer’s Disease Are Waning

More Headwind for the Adenosine A2a Receptor Antagonist Drug Class

The anti-CD20 mAb Drug Class is Anticipated to Reshape the Current Treatment Landscape in Multiple Sclerosis

Digital Health Highlights in Neurology in 2017

Cardiovascular and Metabolic Disorders

Top Players in Cardiovascular Diseases in 2017

Top Players in Metabolic Disorders in 2017

PCSK9 Inhibitors Showed Slow But Steady Growth in Dyslipidemia Market

GLP-1 Receptor Agonist and SGLT-2 Inhibitor Influx for Type 2 Diabetes Continues

Antithrombotics are the Clear Leaders in Sales Among Cardiovascular Drugs

Digital Health Breaks Barriers in the Cardiovascular and Metabolic Space

Infectious Diseases

Top Players in Infectious Diseases in 2017

Vaccines – 2017 Featured Several Notable Approvals and Setbacks

Antibiotics – Small Pharma Steals the Spotlight in 2017

2017 Developments in Digital Health in Infectious Diseases

Ophthalmology

Top Players in Ophthalmology in 2017

Top Trends in Ophthalmology

The Ophthalmology Biosimilars Market Is Still In Its Infancy

Digital Health Highlights in Ophthalmology in 2017

Appendix

Contributors

About GlobalData

Contact Us

Disclaimer

Table

Table 1: 2017 Highlights in Biopharmaceutical R&D Included High-Profile Successes and Failures

Table 2: Digital Advances Provide Promising Solutions for Chronic Disease Management

Table 3: Two Failures Within the 5-HT6 Receptor Antagonist Class Means the Options for Alzheimer’s Disease Are Waning

Table 4: More Headwind for the Adenosine A2a Receptor Antagonist Drug Class

Table 5: Antibiotics – Small Pharma Steals the Spotlight in 2017

Table 6: Trends in Ophthalmology

Figures

Figure 1: Top 10 Companies in Oncology

Figure 2: Top 20 Drugs in Oncology

Figure 3: Key Events in the CAR-T Space in 2017

Figure 4: Checkpoint Immunotherapy Approvals in 2017 and Projected Sales of CPIs in Oncology ($B)

Figure 5: Key Events for Checkpoint Inhibitors in 2017 and Comparison of Ongoing Trials of CPIs in Oncology

Figure 6: Key Events in PARP inhibitors in 2017

Figure 7: Key Events in the Oncology Biosimilar Landscape in 2017

Figure 8: Current and Future Directions in the Oncology Biosimilar Space

Figure 9: Top 10 Companies in Immunology

Figure 10: Top 20 Drugs in Immunology

Figure 11: Proportion of Total Drug Sales Across All JAK Inhibitors

Figure 12: Total Sales for Interleukin Inhibitors in Immunology

Figure 13: Projected Total Sales of Biosimilars Approved as of 2017

Figure 14: Top 10 Companies in Neurology

Figure 15: Top 20 Drugs in Neurology

Figure 16: Key Developments in the 5-HT6 Receptor Antagonist Class in Alzheimer’s Disease in 2017

Figure 17: Projected Total Sales of Injectable Based Therapies for MS

Figure 18: Top 10 Companies in Cardiovascular Diseases

Figure 19: Top 20 Drugs in Cardiovascular Diseases

Figure 20: Top 10 Companies in Metabolic Disorders

Figure 21: Top 20 Drugs in Metabolic Disorders

Figure 22: Historical Global Sales of PCSK9 Inhibitors ($M)

Figure 23: 2017 PCSK9 Inhibitor Global Market Share

Figure 24: 2022 PCSK9 Inhibitor Global Market Share

Figure 25: GLP-1 Receptor Agonist and SGLT-2 Inhibitor Influx for Type 2 Diabetes Continues

Figure 26: Historical and Projected Global Sales of Branded NOACs, Direct Factor Xa Inhibitors ($M)

Figure 27: Top 10 Companies in ID

Figure 28: Top 20 Products in ID

Figure 29: Projected Sales of Heplisav-B ($M)

Figure 30: Projected Market Shares for Herpes Zoster (Shingles) Vaccines Approved as of 2017

Figure 31: Projected Sales of Vabomere vs. Similar Antibiotics

Figure 32: Top 10 Companies in Ophthalmology

Figure 33: Top 20 Drugs in Ophthalmology

Figure 34: Historical Sales of Lucentis and Eylea ($B)

Figure 35: GlobalData’s Forecast Share of Key Ophthalmology Markets in 2016

Figure 36: Projected Total Sales of Biosimilars in Key Ophthalmology Markets

Frequently asked questions

The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area thematic reports
Currency USD
$275

Can be used by individual purchaser only

$825

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area in real time.

  • Access a live The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.